Recent News

• 05.28.2025 - Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro™ Testing Method
• 05.08.2025 - Elutia Q1 2025 Financial Results Call
• 05.08.2025 - Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales
• 05.01.2025 - Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio
• 05.01.2025 - Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025
• 04.29.2025 - Elutia at Chardan’s Trending Issues in Drug Development Conference Series
• 04.23.2025 - Elutia at the Planet Microcap Showcase
• 04.23.2025 - Elutia at the Planet Microcap Showcase
• 04.22.2025 - Elutia to Participate in Chardan’s Trending Issues in Drug Development Conference Series on April 29
• 04.21.2025 - Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice

Recent Filings

• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.08.2025 - EX-99.1 EX-99.1
• 05.08.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 05.08.2025 - 8-K Current report
• 05.06.2025 - 8-K Current report
• 05.06.2025 - EX-99.1 EX-99.1
• 04.11.2025 - 424B5 Prospectus [Rule 424(b)(5)]